Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caladrius Biosciences Inc.

www.caladrius.com

Latest From Caladrius Biosciences Inc.

Caladrius CEO Predicts Tenfold Market Cap Rise As Pipeline ‘Validates’ Itself

The CEO of US-based Caladrius Biosciences believes its share price will rise at least tenfold over the next three years as the cell therapy specialist’s pipeline advances to commercialization.

Cardiovascular Regenerative Medicine

Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters

Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters

Pipeline Watch: Phase III Starts With NSR-REP1 Gene Therapy, ALLN-177 And BIVV009

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

UsernamePublicRestriction

Register